Asset Details
Do you wish to reserve the book?
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Do you wish to request the book?
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
2021
Overview
Patients who had had a relapse after receiving platinum-containing chemotherapy and a PD-1 or PD-L1 immune checkpoint inhibitor were assigned to receive enfortumab vedotin or one of three chemotherapy agents chosen by their doctor. Enfortumab vedotin prolonged progression-free and overall survival.
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antineoplastic Agents, Immunological - adverse effects
/ Antineoplastic Agents, Immunological - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Cell Adhesion Molecules - antagonists & inhibitors
/ Female
/ Humans
/ Male
/ Patients
/ Platinum
/ Programmed Cell Death 1 Ligand 2 Protein - antagonists & inhibitors
/ Programmed Cell Death 1 Receptor - antagonists & inhibitors
/ Urologic Neoplasms - drug therapy
/ Urologic Neoplasms - mortality
